# ShigaToxin_Toxoid_Sequences
Sequences of Shiga toxin subtypes modified to encode a non-toxic (toxoid) mutant of Shiga toxin (Stx). These mutant sequences can be placed in a cloning plasmid and be used as a non-toxic control for PCR, either directly as a plasmid, or as an E. coli transformant. These sequences are intended to provide an accessible option for laboratories to assess the inclusivity of PCR protocols for Shiga toxin genes without biosecurity risks.

The Shiga Toxin Toxoid (stxoid) sequences are altered from the wild type stx sequence, to code for an enzymatically inactive A subunit protein by substituting two amino acids in the active site. The amino acid substitutions are glutamate 167 to glutamine (Hovde et al., 1988) and arginine 170 to leucine (Yamasaki et al., 1991). Shiga toxin proteins with these amino acid substitutions have been demonstrated to have no toxicity in studies with cell cultures, mice, pigs, and calves (Makino et al., 2001; Ishikawa et la., 2003; Ohmura-Hoshino et al., 2004; Wen et al., 2006; Kerner et al., 2015).


NCBI accession numbers and other information used to generate the sequences are in: Accession_Numbers_and_info.txt

Sequences of Shiga toxin Toxoids are in: Shiga_Toxin_Toxoid_Sequences.txt


How to cite:

Provide github link (https://github.com/bmh-vteclab/ShigaToxin_Toxoid_Sequences) along with the current commit number (e.g. c2b6677).


Authors:

Alex Gill, and Tanis McMahon

Bureau of Microbial Hazards, 251 Sir Frederick Banting Driveway, PL2204E, Health Canada, Ottawa, Ontario, K1A 0K9


References

Hovde, C.J., Calderwood, S.B., Mekalanos, J.J., and Collier, R.J. 1988. Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I. Proc Natl Acad Sci U S A. 85:2568–2572. DOI: 10.1073/pnas.85.8.2568

Ishikawa, S., Kawahara, K., Kagami, Y., Isshiki, Y., Kaneko, A., Matsui, H., Okada, N., and Danbara, H. (2003). Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1. Infection and Immunity. 71(6): 3235–3239. DOI:10.1128/IAI.71.6.3235-3239.2003

Kerner, K., Bridger, P.S., Köpf, G., Fröhlich, J., Barth, S., Willems, H., Bauerfeind, R., Baljer, G., and Menge, C. 2015. Evaluation of biological safety in vitro and immunogenicity in vivo of recombinant Escherichia coli Shiga toxoids as candidate vaccines in cattle. Veterinary Research. 46(1):38. DOI: 10.1186/s13567-015-0175-2.

Makino, S., Watarai, M., Tabuchi, H., Shirahata, T., Furuoka, H., Kobayashi, Y., and Takeda, Y. (2001). Genetically modified Shiga toxin 2e (Stx2e) producing Escherichia coli is a vaccine candidate for porcine edema disease. Microbial pathogenesis, 31(1), 1–8. DOI: 10.1006/mpat.2001.0440

Ohmura-Hoshino, M., Yamamoto, M., Yuki, Y., Takeda, Y., and Kiyono, H. (2004). Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity. Vaccine, 22(27-28), 3751–3761. DOI: 10.1016/j.vaccine.2004.03.034

Wen, S. X., Teel, L. D., Judge, N. A., and O'Brien, A. D. 2006. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine, 24(8), 1142–1148. DOI: 10.1016/j.vaccine.2005.08.094

Yamasaki, S., Furutani, M., Ito, K., Igarashi, K., Nishibuchi, M., and Takeda, Y. 1991. Importance of arginine at position 170 of the A subunit of Vero toxin 1 produced by enterohemorrhagic Escherichia coli for toxin activity. Microb Pathog 11:1–9. DOI: 10.1016/0882-4010(91)90088-r
